Half-yearly Report

Half-yearly Report

Eco Animal Health Group Plc

10 December 2013

ECO Animal Health Group plc

(AIM: EAH)

Results for the six months ended 30 September 2013

HIGHLIGHTS

  • 34% increase in gross profit to £6.8 million (2012: £5.1 million)
  • EPS rises to 0.84 pence ( 2012: loss 0.16 pence )
  • Revenue up 34% to £15.3 million (2012: £11.5 million)
  • Earnings before interest, tax, depreciation, amortisation, share based payments and foreign exchange movements, increased by 45% to £2.97 million (2012: £2.01 million)
  • Gross profit margin maintained at 44%, reflecting the improvement in product mix with a greater focus on higher margin business
  • Successful placing post year end raised £11.5 million net to fund growth
  • Demand for Aivlosin® continues to grow strongly and now represents over 70% of total sales
  • Strong performances from BRIC countries with continued progress in North America while Europe is recovering
  • Further Aivlosin® marketing authorisation in Russia received after period end

Peter Lawrence, Executive Chairman of ECO Animal Health Group plc, commented:

“The second half of the year, which traditionally provides the majority of the contribution to our full year results, has started well. The recent granting of important new approvals has further strengthened the Company’s growth prospects and this will be boosted again when additional important marketing authorisations, currently still with the regulatory authorities, are granted. The Group is continuing to build on its exceptional, modern antimicrobial treatments and has already become a force in global animal health markets and this is expected to continue as we deliver further value to our shareholders.”

Contacts:

ECO Animal Health Group plc

Peter Lawrence 020 8336 6190

Spiro Financial

Anthony Spiro 020 8336 6196

Cenkos Securities plc (Nominated Adviser)

Stephen Keys 020 7397 8926

ECO Animal Health Group plc is a leader in the development, registration and marketing of pharmaceutical products for animals. Our products for these global growth markets promote well-being. Our financial goals are achieved through the careful and responsible application of science to generate value for our shareholders.

Chairman’s Statement

I am very pleased to report that ECO Animal Health Group has once again delivered a strong set of results for the six months ended 30 September 2013.

Demand for Aivlosin®, ECO’s patented macrolide antibiotic used for the treatment of a variety of economically important respiratory and enteric (gut) diseases in pigs and poultry, continues to grow strongly. Worldwide demand for animal health products for farmed animals is influenced by several factors ranging from levels of economic activity to outbreaks of disease. It is encouraging to report that in many of the markets we serve, conditions have begun to improve with pork and poultry prices rising and grain prices declining after years of difficult trading conditions for producers.

Financial

Gross profit increased by over 34 percent to a record £ 6.8 million (2012: £5.1 million). The impact of our strategy of focussing on higher margin business is being reflected positively in our financial performance as we progressively switch away from large volume sales of lower margin generic drugs to concentrate on more profitable lines. As a result, the higher margins enjoyed over recent trading periods have been maintained during these last six months.

Sales advanced strongly to £ 15.3 million for the period (2012: £11.4 million), an increase of over 33 per cent, of which the majority of this uplift was attributable to Aivlosin®, our patented antibiotic.

Earnings per share increased to 0.84 pence (2012: loss 0.16 pence) while earnings before interest, tax, depreciation, amortisation, share based payments and foreign exchange movements, amounted to almost £3.0 million (2012: £2.0 million). Our balance sheet remains strong with net cash at the period end of £ 5.7 million and this has increased to £17.6m as at the 6th of December, which includes the proceeds of the recent placing.

In early October, after the period end, the Company raised £11.5 million net of expenses by way of a placing new ordinary shares with a number of new and existing institutional investors. The lengthy cash cycle of the Company, due to supply chain complexity, means that as sales have expanded the working capital demands to finance debtors have increased; the Company also needed to build up sufficient stocks of Aivlosin® in strategic zones to cover up to six months of sales. The Company is grateful to all those who supported the placing so strongly.

Operations

Sales of Aivlosin® are building steadily in Canada and the USA following the successful launch in those major markets in 2012. We also experienced continued good growth from our Chinese subsidiary, Zhejiang ECO Biok Animal Health Products and a strong recovery in Brazil and India. Aivlosin® and the Ecomectin® range of antiparasitic formulations both performed well in Europe reflecting the benefits of a realigned distribution strategy and improved economic prospects in the region. It is also encouraging that the political and economic problems in South America that had negatively impacted on our performance last year appear to be receding and business in that region is back in line with our expectation.

Initial sales of the Aivlosin® premix formulation into Russia, an important pig producing country, have been promising. In early December we were pleased to announce that the Russian Authorities had granted a marketing authorisation for the water soluble granule formulation of Aivlosin® for use in pigs and poultry. Russia is the fourth largest poultry meat producer and seventh largest pork producing country in the world. It has seen annual double-digit growth in pork and poultry meat production in each of the last five years, driven by both domestic demand and import substitution, with accelerating adoption of large scale, intensive production techniques. In October we announced a positive opinion from the Committee for Medicinal Products for Veterinary Use (CVMP) of the European Medicines Agency (EMA) for the use of Aivlosin® 625 mg/g water soluble granules in turkeys. This positive opinion will allow for the medication of drinking water with Aivlosin® for the treatment of respiratory disease associated with Ornithobacterium rhinotracheale (ORT) in turkeys. Aivlosin® is the first antibiotic to be granted approval in Europe for this specific indication, an economically important respiratory disease. Europe has a 30 per cent share of global turkey meat production.

Our Aivlosin® product development and regulatory submissions work on additional disease indications for already approved species and also for new species continues. We are expecting further marketing authorisations to be granted over the coming months which will enlarge our target markets for Aivlosin®with dossiers having been recently submitted in North America and Korea.

As Aivlosin® now accounts for more than 70 per cent of our international sales, the Company needed to build up sufficient stocks in strategic zones to cover up to six months’ sales. The financial constraints imposed by this investment have been addressed by the recent share placing.

Outlook

The second half of the year, which traditionally provides the majority of the contribution to our full year results, has started well. The recent granting of important new approvals for Aivlosin® has further strengthened the Company’s growth prospects which will be boosted again when additional important marketing authorisations, currently still with the regulatory authorities, are granted. The Group is continuing to build on its exceptional, modern antimicrobial treatments and has already become a strong force in global animal health markets and this is expected to continue as we deliver further value to our shareholders.

Peter A Lawrence

Executive Chairman 9th December 2013

 

CONSOLIDATED INCOME STATEMENT

FOR THE SIX MONTHS TO 30 SEPTEMBER 2013
    Six months   Six months   Year ended
to to
30.09.13 30.09.12 31.03.13
Notes (unaudited) (unaudited) (audited)
 
£000 £000 £000
Revenue 3 15,311 11,455 28,986
Cost of sales (8,542) (6,400) (15,883)

 

Gross Profit 6,769 5,055 13,103
 
Other operating income 101 89 179
Administrative expenses (3,990) (3,167) (6,802)
Currency losses (436) (136) (30)
Amortisation of intangible assets (1,131) (1,469) (2,562)
Share based payments (162) (162) (358)

 

Profit from operating activities: 1,151 210 3,530
 
Net finance (expense)/income (153) (78) (214)

 

Profit before income tax 998 132 3,316
 
Income tax (charge)/credit (263) (11) (192)

 

Profit for the period from continuing operations 735 121 3,124

 

Loss for the period on discontinued operations (net of tax) - - (70)

 

Profit for the period 735 121 3,054
 
Attributable to:
Owners 444 (83) 2,617
Minority interest 291 204 437

 

735 121 3,054

 

 
BASIC (LOSS)/EARNINGS PER SHARE 6 0.84p (0.16)p 4.98p
 
FULLY DILUTED (LOSS)/EARNINGS PER SHARE 6 0.82p (0.16)p 4.90p
 

Earnings from continuing activities before interest,

 

 

 

taxation, depreciation, amortisation, and share based payments.

2,534

1,900

6,640

Exclude foreign exchange differences 436 136 30

 

EBITDA (audit basis) 2,970 2,036 6,670
============= ============= =============
CONSOLIDATED STATEMENT OF COMPREHENSIVE INCOME
FOR THE SIX MONTHS TO 30 SEPTEMBER 2013
  Six months   Six months   Year ended
to to
30.09.13 30.09.12 31.03.13
(unaudited) (unaudited) (audited)
 
£000 £000 £000
Profit for the period 735 121 3,054
 
Foreign currency translation differences (383) (18) 247
Defined benefit pension plan – actuarial gains/(losses) - - 57
Revaluation of freehold property - - 28
Deferred tax on revaluation - - (3)

 

Other comprehensive income for the period (383) (18) 329

=========

========= =========
Total comprehensive income for the period 352 103 3,383

=========

========= =========
 
Attributable to:
Owners 127 (73) 2,816
Minority interest 225 176 567

 

352 103 3,383

 

========= ======== =========
 
CONSOLIDATED STATEMENT OF CHANGES IN EQUITY FOR THE SIX MONTHS TO 30 SEPTEMBER 2013
                 
Share Share Other Revaluation Treasury Retained Total Minority Total
Capital Premium Reserves Reserves Reserve Earnings Interest Equity
Account Account
£000 £000 £000 £000 £000 £000 £000 £000 £000
 
At 1 April 2012 2,756 37,607 4,774 499 (5,218) 15,938 56,356 1,892 58,248
Total comprehensive income for the period:
Profit for the period - - - - - 2,617 2,617 437 3,054
Other comprehensive income
Revaluation of freehold property - - - 28 - - 28 - 28
Tax effect of revaluation of freehold property - - - (3) - - (3) - (3)
Foreign currency translation differences - - - - - 117 117 130 247
Actuarial gains on pension scheme assets

-

- - - - 57 57 - 57
Total comprehensive income for the period - - - 25 - 2,791 2,816 567 3,383

CONSOLIDATED STATEMENT OF CHANGES IN EQUITY FOR THE SIX MONTHS TO 30 SEPTEMBER 2013 CONTINUED.

  £000   £000   £000   £000   £000   £000   £000   £000   £000
Transactions with owners
Arising on issue of shares in the period 11 274 - - - - 285 - 285
Dividends - - - - - (1,982) (1,982) - (1,982)
Share based payments - - 358 - - - 358 - 358
Transfer to retained earnings on option expiry - - (82) - - (82) - - -
Total transactions with owners 11 274 276 - - (1,900) (1,339) - (1,339)
At 31 March 2013 2,767 37,881 5,050 524 (5,218) 16,829 57,833 2,459 60,292
 
Total comprehensive income for the period:
(Loss)/profit for the period - - - - - 444 444 291 735
Other comprehensive income
Foreign currency translation differences - - - - - (317) (317) (66) (383)
Total comprehensive income for the period - - -     127 127 225 352
Transactions with owners
Arising on issue of shares in the period 2 29 - - - - 31 - 31
Share based payments - - 162 - - - 162 - 162
Transfer to retained earnings on option expiry - - (290) - - 290 - - -
Dividends - - - - - - - (800) (800)
Total transactions with owners 2 29 (128) - - 290 193 (800) (607)
At 30 September 2013 2,769 37,910 4,922 524 (5,218) 17,246 58,153 1,884 60,037
 
Prior interim period
At 1 April 2012 2,756 37,607 4,774 499 (5,218) 15,938 56,356 1,892 58,248
Total comprehensive income for the period:
Profit for the period - - - - - (83) (83) 204 121
Other comprehensive income
Foreign currency translation differences - - - - - 10 10 (28) (18)
Total comprehensive income for the period - - - - - (73) (73) 176 103
Transactions with owners
Share based payments - - 162 - - - 162 - 162
Total transactions with owners - - 162 - - - 162 - 162
At 30 September 2012 2,756 37,607 4,936 499 (5,218) 15,865 56,445 2,068 58,513
 

 

 

 

CONSOLIDATED STATEMENT OF FINANCIAL POSITION

     
As at As at As at
30.09.13 30.09.12 31.03.13
(unaudited) (unaudited) (audited)
Notes £000 £000 £000
 
ASSETS
Non current assets
Goodwill and other intangibles 9 42,059 40,056 41,169
Property, plant and equipment 10 1,079 1,179 1,176
Investment property 11 150 153 152
Investments 9 9 9
43,297 41,397 42,506
Current assets
Inventories 5,634 6,176 6,426
Trade and other receivables 9,579 9,262 11,249
Income tax recoverable 19 17 23
Other taxes and social security 180 224 171
Cash and cash equivalents 5,723 8,033 9,664
21,135 23,712 27,533
Total assets 64,432 65,109 70,039
 
Current liabilities
Trade and other payables (3,809) (5,384) (6,916)
Short term borrowings - (746) (2,135)
Income tax (100) (67) (174)
Other taxes and social security (234) (130) (258)
Dividends (32) (30) (32)
(4,175) (6,357) (9,515)
Total assets less current liabilities 60,257 58,752 60,524
 
Non current liabilities
Deferred tax (220) (239) (232)
60,037 58,513 60,292
Equity
Capital and reserves
Called up share capital 2,769 2,756 2,767
Share premium 37,910 37,607 37,881
Treasury Reserve (5,218) (5,218) (5,218)
Revaluation reserve 524 499 524
Other reserves 4,922 4,936 5,050
Retained earnings 17,246 15,865 16,829
58,153 56,445 57,833
Minority interest 1,884 2,068 2,459
Total equity 60,037 58,513 60,292
 

 

CONSOLIDATED STATEMENT OF CASH FLOWS

Six months to   Six months to   Year ended
30.09.13 30.09.12 31.03.13
(unaudited) (unaudited) (audited)
£000 £000 £000
Profit before tax 998 132 3,246
Adjustment for:
Net finance costs 153 78 214
Depreciation of plant and equipment 90 59 190
Amortisation of intangible assets 1,131 1,469 2,562
Pension payments - - (60)
Pension operating costs - - 4
Share based payments 162 162 358
Operating cash flow before movement in working capital 2,534 1,900 6,514
Change in inventories 792 (1,759) (2,009)
Change in receivables 1,661 1,562 (258)
Change in payables (3,131) (1,351) 311
Cash generated from operations 1,856 352 4,558
Interest paid (5) (3) (39)
Income tax (paid)/received (345) (94) (186)
Net cash inflow from operating activities 1,506 255 4,333
Cash flows from investing activities
Purchase of property plant and equipment (17) (14) (39)
Sale of motor vehicle 14 - -
Costs of acquiring drug registrations (2,021) (2,411) (4,619)
Interest received - 35 56
Net cash (used in) investing activities (2,024) (2,390) (4,602)
Cash flows from financing activities
Issue of shares 31 - 245
Dividends paid (800) - (1,942)
Net cash (used in) financing activities (769) - (1,697)
Net (decrease) in cash and cash equivalents (1,287) (2,135) (1,966)
Foreign exchange movements (519) (87) (14)
Cash and cash equivalents at the beginning of the period 7,529 9,509 9,509
Cash and cash equivalents at the end of the period 5,723 7,287 7,529

NOTES TO THE PRELIMINARY RESULTS FOR THE SIX MONTHS TO 30 SEPTEMBER 2013

1. Basis of preparation

The financial information for the period to 30 September 2013 does not constitute statutory accounts as defined by Section 435 of the Companies Act 2006. It has been prepared in accordance with the accounting policies set out in, and is consistent with, the audited financial statements for the twelve months to 31 March 2013.

The Group applies revised IAS 1 “Presentation of Financial Statements (2007)”, which became effective as of 1 January 2009. As a result, the Group presents all non owner changes in equity in consolidated statements of comprehensive income and all owner changes in equity in consolidated statements of changes in equity.

2. Statement of compliance

The interim financial statements do not include all of the information required for full annual financial statements and do not comply with all of the disclosure requirements in IAS 34 “Interim Financial Reporting”. Accordingly, whilst the interim statements have been prepared in accordance with IFRS, they cannot be construed as being in full compliance with IFRS and should be read in conjunction with the consolidated financial statements of the Group for the year ended 31 March 2013.

3. Revenue is derived from the Group’s animal pharmaceutical businesses.

4. Change in accounting estimate

Following the receipt of the marketing authorisation for Water Soluble Aivlosin in the USA in July 2012, the directors changed their estimate of the useful life of Aivlosin drug registrations from ten to twenty years and have therefore amortised the remaining value of this asset over the extended remaining useful life with effect from 1st July 2012. Details of the effect of this change in an accounting estimate can be found in Note 2.9 of the consolidated financial statements of the Group for the year ended 31 March 2013.

5. Principal risks and uncertainties

These were set out on pages 59-62 of the notes to the consolidated financial statements for the year ended 31 March 2013. The key exposures are to foreign currency exchange rates, potential delays in obtaining marketing authorisations and single sources of supply for some raw materials and have remained unchanged since the year end.

6. Earnings per share

  Six months to   Six months to   Year ended
30.09.13 30.09.12 31.03.13
(unaudited) (unaudited) (audited)
 
 
 
Weighted average number of shares in issue (000’s) 52,759 52,516 52,599
Fully diluted weighted average number of shares in issue (000’s) 53,860 53,278 53,388
 
Profit/(loss) attributable to equity holders of the company (£’s) 442,842 (83,572) 2,616,892
 
Basic earnings/(loss) per share (pence) 0.84 (0.16) 4.98
Fully diluted earnings/(loss) per share (pence) 0.82 (0.16) 4.90

7. Dividends

  Six months to   Six months to   Year ended
30.09.13 30.09.12 31.03.13
(unaudited) (unaudited) (audited)
 
£000 £000 £000
 
Dividend in respect of the year ended 31 March 2013

55,376,006 (2012: 55,119,201) shares at nil (2012:

3.75p) per share

Dividend waived by employee benefit trust

-

-

-

-

2,067

(84)

 

- - 1,983
========= ========= =========

An interim dividend of 4.0p per share was paid on 25 October 2013, amounting to £2,215,040. The Employee Benefit Trust waived dividends of £102,590 resulting in a net dividend figure of £2,112,450.

8. Related party transactions

At the period end, ECO Animal Health Group plc owed P A Lawrence, a director of ECO Animal Health Group plc, and members of his family a balance amounting to £101,901 (30 September 2012: £9,457). During the period the Group provided management services to Anpario plc and C-Corp Limited, companies in which P A Lawrence is a director and holds equity interests. Fees charged were: Anpario plc £16,250 (2012: £13,000) and C-Corp Limited £21,699 (2012: £21,726).

During the period the Group made sales to Zhejiang ECO Biok Animal Health Products Limited at an arm’s length basis to the value of £1,080,347 (Six months to 30 September 2012: £634,435). At the end of this period there was an intercompany balance owing from this company of £515,298 (30 September 2012: £591,033).

The Group also made sales on an arm’s length basis to ECO Animal Health do Brasil Comercio de Productos Veterinarios Ltda to the value of £1,110,482 (Six months to 30 September 2012 £1,098,457). At the end of the period there was an intercompany balance of £551,596 (30 September 2012: £1,983,522).

The Group also made sales on an arm’s length basis to ECOpharma Inc to the value of £407,745 (30 September 2012: £450,273). At the end of the period there was an intercompany balance of £135,007 (30 September 2012: £258,672).

The Group also made sales on an arm’s length basis to ECO Animal Health de Mexico to the value of £247,393 (Six months to September 2012: nil). At the end of the period there was an inter company balance of £802,198 (30 September 2012: £176,848)

The Group also made sales on an arm’s length basis to ECO Animal Health USA Corp to the value of £502,576 (six months to 30 September 2012: £281,899). At the end of the period there was an inter company balance of £723,780 (30 September 2012: £353,439).

The Group also made sales on an arm’s length basis to Pharmgate Animal Health Canada Inc to the value of £200,137 (six months to September 2012: £56,250). At the end of the period there was an inter company balance of £61,900 (30 September 2012: £44,982).

All of the transactions have been eliminated on consolidation, as well as the whole of the balances relating to the subsidiaries and the group’s share of the balances relating to the US and Canadian joint ventures. During the period ECO Animal Health Ltd and ECO Animal Health Group plc received dividends of £831,764 (2012: £nil) from Zhejiang ECO Biok Animal Health Products Limited.

9. Intangible non current assets

    Distribution   Development  
Goodwill Rights Costs Total
£000 £000 £000 £000
Cost
Cost at 1 April 2012 17,930 1,035 39,524 58,489
 
Additions - - 2,411 2,411

 

Cost at 30 September 2012 17,930 1,035 41,935 60,900
 
Additions - 231 1,977 2,208

 

 

 

 

Cost at 31 March 2013 17,930 1,266 43,912 63,108
             
Additions - - 2,021 2,021

 

 

 

 

 

 

 

Cost at 30 September 2012 17,930 1,266 45,933 65,129

 

Amortisation
Amortisation at 1 April 2012 - 422 18,958 19,380
 
Charge for the period - 28 1,441 1,469
Foreign exchange movements - - (5) (5)

 

Amortisation at 30 September 2012 - 450 20,394 20,844
 
Charge for the period - 31 1,063 1,094
Foreign exchange movements - - 1 1

 

Amortisation at 31 March 2013 - 481 21,458 21,939
 
Charge for the period - 31 1,100 1,131

 

Amortisation at 30 September 2013 - 512 22,558 23,070

 

 
Net book value at 30 September 2013

17,930

754

23,375

42,059

======== ======== ======== ========
Net book value at 1 April 2013 17,930 785 22,454 41,169
======== ======== ======== ========
Net book value at 30 September 2012 17,930 585 21,541 40,056
======== ======== ======== ========
Net book value at 1 April 2012 17,930 613 20,566 39,109
======== ======== ======== ========

10. Property, plant and equipment

Fixtures

Motor

Freehold Plant and fittings & Vehicles
property machinery equipment Total
£000 £000 £000 £000 £000
Cost
Cost at 1 April 2012 650 1,185 627 102 2,564
 
Additions - 7 7 - 14
Foreign exchange movements - (14) - - (14)

 

Cost at 30 September 2012 650 1,178 634 102 2,564
 
Additions - 9 15 - 24
Foreign exchange movements - 79 - - 79

 

Cost at 1 April 2013 650 1,266 649 102 2,667
Additions - 12 5 - 17
Disposals - - - (27) (27)
Foreign exchange movements - (41) (1) - (42)

 

Cost at 30 September 2013 650 1,237 653 75 2,615

 

Depreciation
Depreciation at 1 April 2012 18 724 528 26 1,296
 
Charge for the period 5 16 21 15 57
Foreign exchange movements - 32 - - 32

 

Depreciation at 30 September 2012 23 772 549 41 1,385
 
Charge for the period 5 103 12 11 131
Revaluations (28) - - - (28)
Foreign exchange movements - 7 (4) - 3

 

Depreciation at 1 April 2013 - 882 557 52 1,491
 
Charge for the period 5 58 17 8 88
Disposals - - - (13) (13)
Foreign exchange movements - (30) - - (30)

 

Depreciation at 30 September 2013 5 910 574 47 1,536

 

 
Net book value
Net book value at 30 September 2013 645 327 79 28 1,079
======== ======== ======== ========= ==========
Net book value at 1 April 2013 650 384 92 50 1,176
======== ======== ======== ========= ==========
Net book value at 30 September 2012 627 406 85 61 1,179
======== ======== ======== ========= ==========
Net book value at 1 April 2012 632 461 99 76 1,268
======== ======== ======== ========= ==========

11. Investment property

Freehold Property Total
Cost £000 £000
Cost at 31 April through to 30 September 2013 157 157
======== ========
Depreciation
Depreciation at 1 April 2012 2 2
 
Charge for the period ended 30 September 2012 2 2

 

Depreciation at 30 September 2012 4 4
Charge for the period ended 31 March 2013 1 1

 

Depreciation at 31 March 2013 5 5
Charge for the period ended 30 September 2013 2 2

 

Depreciation at 30 September 2013 7 7
======== ========
Net book value
Net book value at 30 September 2013 150 150
======== ========
Net book value at 31 March 2013 152 152
======== ========
Net book value at 30 September 2012 153 153
======== ========
Net book value at 1 April 2012 155 155
======== ========

12. Post Balance Sheet Event

The Company placed 6,315,790 new ordinary shares at a price of 190p per share on 23rd October 2013, raising £11.5m net of expenses. A further 737,595 shares were also issued on the same date as the result of the exercise of employee options, raising a further £1.1m.

13. This financial information was approved by the board on 09 December 2013.

Copies of this interim report are being sent to all of the Company’s shareholders. Further copies can be obtained from the Company’s registered office at 78 Coombe Road, New Malden, Surrey KT3 4QS.

DIRECTORS AND OFFICERS   Peter Lawrence   (Chairman)
Marc Loomes (Chief Executive)
Kevin Stockdale (Finance Director)
Julia Trouse (Executive Director and Company secretary)
Brett Clemo (Executive Director)
David Danson (Non-Executive Director)
Julia Henderson (Non-Executive Director)
 
REGISTERED OFFICE 78 Coombe Road, New Malden, Surrey. KT3 4QS
Tel: 020-8336-2900 Fax: 020-8336-0909
 
COMPANY NUMBER 01818170

Companies

ECO Animal Health Group (EAH)
UK 100
FTSE quotes by TradingView

Latest directors dealings

All directors dealings today